Synergy Pharma Cmn (SGYP) 3.97 $SGYP Synergy

New Post Public Reply Private Reply Replies (0) Message Board

Jun 11, 2016 at 11:02 AM

Synergy Pharma Cmn (SGYP) 3.97 $SGYP

Synergy Pharmaceuticals Presents New In Vitro Data Showing the pH-Dependent Activity of Plecanatide Replicates That of Naturally Occurring GI Peptide Uroguanylin
BusinessWire - Tue May 24, 12:36PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today presented new in vitro data at Digestive Disease Week (DDW) showing plecanatide, an investigational compound being evaluated for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), replicated the pH-dependent activity of the body's naturally occurring gastrointestinal (GI) peptide - uroguanylin. Uroguanylin plays an important role in supporting regular bowel function through its activation of the intestinal guanylate cyclase C (GC-C) receptor.
SGYP: 3.97 (-0.03)

Synergy Pharmaceuticals Presents New Plecanatide Phase 3 Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sun May 22, 11:30AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional results from the second of two pivotal phase 3 clinical trials evaluating the efficacy and safety of plecanatide, the company's first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 3.97 (-0.03)

Synergy Pharmaceuticals Presents Additional Phase 3 Plecanatide Data in Chronic Idiopathic Constipation at Digestive Disease Week
BusinessWire - Sat May 21, 11:31AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced additional data from two pivotal phase 3 clinical trials (Study-00 and Study-03) evaluating the efficacy and safety of plecanatide, a once-daily oral tablet, in treating patients with chronic idiopathic constipation (CIC). Data were presented at Digestive Disease Week (DDW) in San Diego.
SGYP: 3.97 (-0.03)

Synergy Pharmaceuticals to Present New Plecanatide Data at Digestive Disease Week 2016
BusinessWire - Mon May 16, 8:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ: SGYP) today announced that the company will present data on plecanatide, the first uroguanylin analog being evaluated for the treatment of chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C), at Digestive Disease Week 2016 in San Diego, May 21-24.
SGYP: 3.97 (-0.03)

Synergy Pharma reports 1Q loss
Automated Insights - Tue May 10, 5:20PM CDT
NEW YORK (AP) _ Synergy Pharmaceuticals Inc. (SGYP) on Tuesday reported a loss of $59.9 million in its first quarter.
SGYP: 3.97 (-0.03)

Synergy Pharmaceuticals Reports First Quarter 2016 Financial Results and Business Update
BusinessWire - Tue May 10, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today reported its financial results and business update for the three months ended March 31, 2016.
SGYP: 3.97 (-0.03)

Synergy Pharmaceuticals Inc. Announces Closing of $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Mon May 09, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has closed a registered direct offering of $89.8 million of common stock at a price of $3.00 per share.
SGYP: 3.97 (-0.03)

Synergy Pharmaceuticals Inc. Announces $89.8 Million Registered Direct Offering of Common Stock
BusinessWire - Thu May 05, 7:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced that it has entered into definitive agreements with certain institutional investors to sell 29,948,334 shares of common stock at a price of $3.00 per share.
SGYP: 3.97 (-0.03)

Why Synergy Pharmaceuticals Shares Jumped 15.4% in April
Todd Campbell, The Motley Fool - Motley Fool - Tue May 03, 3:01PM CDT
Image source: Synergy Pharmaceuticals. What: After the FDA officially accepted a filing for approval of its lead product candidate, shares of Synergy Pharmaceuticals were sent soaring 15.4% last month, according to data from S&P Global...
SGYP: 3.97 (-0.03), AGN: 240.93 (-6.47), IRWD: 12.87 (-0.13)

These Stocks Are Starting To Catch Wall Street's Attention
ACCESSWIRE - Fri Apr 29, 8:35AM CDT
NEW YORK, NY / ACCESSWIRE / April 29, 2016 / InvestmentResearchReport.com is a small cap publication that uncovers extremely undervalued potential investment opportunities that have been overlooked by everyone else. Today we are taking a look at five companies which we believe could provide investors with potential upside volatility in the near term.
SGYP: 3.97 (-0.03)

Synergy Pharmaceuticals Announces Resignation of Chief Financial Officer
BusinessWire - Wed Apr 27, 3:30PM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced that Gary L. Sender has resigned as the company's Chief Financial Officer for personal reasons, effective April 30, 2016. Bernard F. Denoyer, who has served as Senior Vice President of Finance and Secretary at Synergy since 2008, will assume responsibilities as Principal Financial Officer.
SGYP: 3.97 (-0.03)

Synergy Pharmaceuticals to Present at the Deutsche Bank Health Care Conference
BusinessWire - Tue Apr 26, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP) today announced the company is scheduled to present a corporate update at the 41st Annual Deutsche Bank Health Care Conference on Wednesday, May 4,2016 at 2:50 p.m. Eastern Time.
SGYP: 3.97 (-0.03), DB: 15.74 (-0.97)

Global Constipation Market: Vast Opportunity for New Drug Entry - Key Players are AstraZeneca, Ironwood Pharmaceuticals & Synergy Pharmaceuticals - Research and Markets
BusinessWire - Fri Apr 22, 5:18AM CDT
Research and Markets has announced the addition of the "Global Constipation Market Report: 2016 Edition" report to their offering.
SGYP: 3.97 (-0.03), IRWD: 12.87 (-0.13)

What's Behind Synergy Pharmaceuticals' Soaring Shares Today
Todd Campbell, The Motley Fool - Motley Fool - Tue Apr 19, 3:03PM CDT
Image source: Synergy Pharmaceuticals. What: After reporting that the FDA has officially accepted its application for the approval of plecanatide, shares of Synergy Pharmaceuticals are gaining 10.5% at 3:30 p.m. EDT today. So what:...
SGYP: 3.97 (-0.03), AGN: 240.93 (-6.47), IRWD: 12.87 (-0.13)

These Four Biotech Stocks Are Trading With Massive Volume Today
ACCESSWIRE - Tue Apr 19, 9:05AM CDT
NEW YORK, NY / ACCESSWIRE / April 19, 2016 / The Stock Expert is issuing a report on four stocks that are trading with heavier than usual volume. SGYP, RPRX, CPXX and HRTX are on high volume alert. Continue reading to find out why. - To get daily alerts on the hottest stocks on the Nasdaq/NYSE subscribe to our newsletter at TheStockExpert.com.
CPXX: 30.24 (+0.08), SGYP: 3.97 (-0.03), HRTX: 19.17 (-0.42), RPRX: 1.70 (-0.08)

Synergy Pharmaceuticals Announces Acceptance of New Drug Application for Plecanatide, a Novel Uroguanylin Analog, in Chronic Idiopathic Constipation
BusinessWire - Tue Apr 19, 5:00AM CDT
Synergy Pharmaceuticals Inc. (NASDAQ:SGYP), a biopharmaceutical company focused on the development and commercialization of novel gastrointestinal (GI) therapies, today announced the U.S. Food and Drug Administration (FDA) has determined that the company's New Drug Application (NDA) for plecanatide, its first uroguanylin analog, for the treatment of chronic idiopathic constipation (CIC) is sufficiently complete to permit a substantive review. The FDA Prescription Drug User Fee Act (PDUFA) target action date is January 29, 2017.
SGYP: 3.97 (-0.03)

Why Are These 4 Stocks So Volatile Today?
ACCESSWIRE - Mon Apr 11, 9:31AM CDT
These Small Cap Stocks Are Getting Major Attention Today
SGYP: 3.97 (-0.03), CANF: 2.81 (-0.05), OMEX: 2.16 (-0.07), MNKD: 1.01 (-0.02)

3 Biotech Stocks With Scary-High Debt-to-Capital Ratios
Todd Campbell, The Motley Fool - Motley Fool - Mon Apr 11, 7:40AM CDT
SOURCE: FLICKR USER GOTCREDIT.COM. Biotech companies pour millions of dollars into research programs that may or may not pan out, and money to fund that research can come from issuing stock or taking on debt. Debt isn't always a bad thing, but too...
SGYP: 3.97 (-0.03), MACK: 6.32 (-0.24), IRWD: 12.87 (-0.13), AMRN: 2.12 (-0.09)

Synergy Pharmaceuticals (SGYP) Jumps: Stock Gains 6.1%
Zacks Equity Research - Zacks Investment Research - Mon Mar 28, 7:00AM CDT
Synergy Pharmaceuticals (SGYP) was a big mover last session, with its shares rising over 6% on the day.
SGYP: 3.97 (-0.03), ADHD: 5.10 (-0.13)

Is This Ironwood Pharmaceuticals' Biggest Threat?
Todd Campbell, The Motley Fool - Motley Fool - Mon Mar 21, 7:41AM CDT
SOURCE: SYNERGY PHARMACEUTICALS. Ironwood Pharmaceuticals has big plans to become a major player in biopharma, but sales of its constipation drug Linzess will need to keep growing if Ironwood is going to execute on those plans. Although Linzess...
SGYP: 3.97 (-0.03), AGN: 240.93 (-6.47), IRWD: 12.87 (-0.13), AZN: 27.97 (-0.99)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Ex-Guard Pushes Cost-Saving Grille Guards as Deer Season Hits

Deer Season's Bumper Problem If you're driving a hefty pickup or van in the thick of deer season, forget looking at pretty autumn leaves. Instead, brace for the telltale thud—and the ensuing financial headache—that comes with a deer collision. Anyone who's tangled with such a mishap knows it's not just about the dent in your fender; it's about your wallet getting...

Meitu Sees Soaring Subscriber Growth Amid AI Focus

Subscriber Growth Hits a Record High Well, here's a headline to chew on—Meitu, Inc. is boasting a whopping 19.83 million paying subscribers, setting a new milestone. That's 1.39 million new users this quarter alone, the most significant uptick they've seen in four cycles. Not that I'm surprised; when you've got a product mix like theirs that's riding high on the wave of...

Nicely Network: A Game-Changer for B2B SaaS Marketing

Navigating the Reddit Marketing Labyrinth Life ain't a walk in the park for marketers these days, especially in the tech and SaaS arenas. Some folks seem to have cracked the code—or at least one part of it. Enter Nicely Network, which has just snagged the crown as the Best Reddit Marketing Agency for B2B SaaS & Software Companies, thanks to its knack for connecting...

Tabañero Spices Up Holidays with $10 Gift Sets

Hot Sauce, Spicy Gifting, and Bold Barbecue When holiday cheer mixes with a dash of heat, you end up with something as electrifying as Tabañero's latest offerings. This Florida-based player is nudging its way into the gift-giving scene with a lineup that's as spicy as it is thoughtful. Frankly, if you're scrambling for stocking stuffers or a memorable Secret Santa...

Honeywell Aerospace Posts Solid Q3, Raises Guidance

Honeywell Aerospace Surprises with Strong Third Quarter In a world where numbers are often as slippery as a greased pig, Honeywell Aerospace (NASDAQ:HONA) has managed to pin down a surprisingly robust third quarter. Let’s break it down: they’ve claimed sales of a cool $4.6 billion, reflecting a 2% bump both in reported and organic revenue from the previous year, and...

ZYNLONTA's Japanese Push: ADC Therapeutics Gains Traction

ADC Therapeutics Eyes Japan with ZYNLONTA Bet These days, everyone seems to have their eyes on the Far East, and ADC Therapeutics is no exception. They're making a strategic leap by letting their budding blockbuster ZYNLONTA make waves in Japan. With the fresh file submitted for approval, it looks like they're hoping to capture market ground that could pay off big time...

Factory-Built Homes Take Center Stage in New Doc Short

Housing is one of those things we all think we understand until we start peeling back the layers of its history, especially when factory-built homes are involved. Here's a new angle: Clayton has just released the teaser for their documentary short, "Built: A Story of Factory-Built Housing in America," and it's turning the lights on a sector that's often left in the...

Virax Biolabs Expands China Reach With Key Partnerships

Virax Biolabs' Strategic Play in China Does Virax Biolabs have a trick up its sleeve, or is it just rolling the dice in the vast Chinese market? With three new distributor agreements, it sure seems like it's trying to tip the scales in its favor. The London-based company announced new distribution agreements for its ImmuneSelect research-use immune profiling products....

Withings Sleep Care Service Tackles Post-Time Change Fatigue

Counting Sheep: More Minutes or Just More Trouble? As Americans prepare for the clocks to fall back, many dream of an extra hour of sleep. But according to Withings, the reality is far less restful. Despite the clock change promising more shut-eye, folks average just 11 minutes extra sleep, only to watch that dissipate in the days following. Somehow, we lose more than we...

Corgi Revamps Malpractice Insurance for Healthcare Sector

Streamlining Insurance for Healthcare Professionals Here's one for the books in the insurance world: Corgi Insurance is stepping up to spare healthcare practices from the headache of getting medical malpractice coverage. This is more than just insurance talk; it's about time someone carved out a path through the labyrinth of medical malpractice policies. Healthcare folks...